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Abstract
Background: Numerous observational studies suggest that preventable adverse drug reactions are a significant burden in
healthcare, but no meta-analysis using a standardised definition for adverse drug reactions exists. The aim of the study was
to estimate the percentage of patients with preventable adverse drug reactions and the preventability of adverse drug
reactions in adult outpatients and inpatients.
Methods: Studies were identified through searching Cochrane, CINAHL, EMBASE, IPA, Medline, PsycINFO and Web of
Science in September 2010, and by hand searching the reference lists of identified papers. Original peer-reviewed research
articles in English that defined adverse drug reactions according to WHO’s or similar definition and assessed preventability
were included. Disease or treatment specific studies were excluded. Meta-analysis on the percentage of patients with
preventable adverse drug reactions and the preventability of adverse drug reactions was conducted.
Results: Data were analysed from 16 original studies on outpatients with 48797 emergency visits or hospital admissions and
from 8 studies involving 24128 inpatients. No studies in primary care were identified. Among adult outpatients, 2.0% (95%
confidence interval (CI): 1.2–3.2%) had preventable adverse drug reactions and 52% (95% CI: 42–62%) of adverse drug
reactions were preventable. Among inpatients, 1.6% (95% CI: 0.1–51%) had preventable adverse drug reactions and 45%
(95% CI: 33–58%) of adverse drug reactions were preventable.
Conclusions: This meta-analysis corroborates that preventable adverse drug reactions are a significant burden to healthcare
among adult outpatients. Among both outpatients and inpatients, approximately half of adverse drug reactions are
preventable, demonstrating that further evidence on prevention strategies is required. The percentage of patients with
preventable adverse drug reactions among inpatients and in primary care is largely unknown and should be investigated in
future research.
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Introduction
Drug-related adverse events, including adverse drug reactions
(ADRs), have been reported to be among leading causes of
morbidity and mortality [1,2]. ADRs occur in both outpatients
and inpatients [2-7]. In a meta-analysis in 2002, 4.9% of hospital
admissions were associated with ADRs, ranging between 0.2 and
41.3% in individual studies [4]. Further, 28.9% of the ADR-
related hospitalisations were considered preventable. Of inpa-
tients, 10.9% is estimated to experience an ADR during
hospitalisation [2]. According to the World Health Organization
(WHO), costs of ADRs, including hospitalisations, surgery and lost
productivity, exceed the cost of medicines in some countries [8].
As drug-related adverse events are estimated to cost USD 422–
7062 per drug-related admission and USD 2284–5640 per
inpatient with drug-related adverse events (2000 values) [9],
significant costs may be saved if drug-related adverse events,
including ADRs, were prevented.
Previous review studies have investigated preventable drug-
related adverse events and the preventability of the events [4,6,10-
13]. However, most of them summarised studies on all drug-
related adverse events, including adverse events due to noncom-
pliance and overdose, without a clear definition for the adverse
event, and used medians as summary measures [6,11-13]. Two
previous reviews investigated the preventability of ADRs among
outpatients being admitted to hospital [4,10], but no standardised
definition for ADRs was required, outpatients without hospital-
isation were not studied and no meta-analysis technique was used
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33236to pool the results. Further, no previous review has investigated the
preventability of ADRs among inpatients or the percentage of
outpatients or inpatients with preventable ADRs (PADRs).
Therefore, we applied meta-analysis techniques using a standard-
ised definition for ADRs to estimate the percentage of adult
outpatients and inpatients with PADRs, and the preventability of
ADRs.
Methods
We carried out a meta-analysis on studies on PADRs in adults,
adapting methods recommended by the Statement for Reporting
Systematic Reviews and Meta-analyses [14], and following our
study protocol. We searched seven databases; MEDLINE,
Excerpta Medica Database (EMBASE), the Cochrane database
of systematic reviews, Cumulative Index to Nursing & Allied
Health Literature (CINAHL), International Pharmaceutical Ab-
stract (IPA), PsycINFO and Web of Science (–September 2010) for
relevant publications. References of included articles and previous
reviews and meta-analysis on ADRs were reviewed to identify
additional relevant articles and consider their inclusion.
The databases’ search fields for titles, abstracts and index terms
were searched using the databases’ index terms and other
commonly utilised terminology on drug-related adverse events
and preventability (Figure 1). No limits for the years of publication
were set. The search was limited to English. Multiple publications
of the same study were carefully reviewed [15]. The titles and
abstracts were screened by one researcher (KMH). Studies were
selected for inclusion from full-text articles in collaboration by two
researchers (KH, KMH). An additional reviewer (SH) participated
in the review process when uncertainty about eligibility criteria
arose.
We included original peer-reviewed research articles published in
English regardless of the study design (prospective, retrospective,
cross-sectional, or interventional). To avoid inconsistent estimates,
ADRs had to be defined according to the WHO: ‘‘a response which is
noxious and unintended, and which occurs at doses normally used in humans for
the prophylaxis, diagnosis, or therapy of disease, or for the modification of
physiological function’’ [16], or according to Edwards and Aronson’s
similar definition [17]. Small changes in wording were overlooked if
thetworesearchers(KH,KMH)agreed thatthefunctionalmeaning
remained the same. Studies representing one or two specific disease
areas (inclusion of patients, setting or sampling frame) or specific
treatments were excluded. Included studies had to report the
percentage of patients with PADRs or the preventability of ADRs.
We excluded articles summarising previous results without original
assessment of ADRs and the preventability of ADRs and studies
conducted in paediatrics or intensive care, or focusing only on
specific types of, life threatening or fatal ADRs. We also excluded
studies if ADRs were identified exclusively through spontaneous
reporting or International Classification Disease (ICD-9 or 10)
codes, as these two strategies are known to underestimate the rate of
ADRs [7,18]. Although we set no limitations on how preventability
must be defined in original studies, we required a case by case
preventability assessment. Thus, we excluded studies that consid-
ered all type A ADRs, defined as dose dependent and predictable
from the known pharmacological characteristics of the drug [19], as
preventable without a separate preventability assessment. Studies
were also excluded if the percentage of patients with PADRs and
preventability of ADRs were inadequately reported.
Data extraction
To increase the reliability and efficiency of data extraction, we
developed and piloted a paper data extraction form by adapting
the checklist for Strengthening the Reporting of Observational
Studies in Epidemiology [20]. Studies’ characteristics such as the
study design, data source, sampling frame, population character-
istics, and definition for ADRs, as well as the number of included
patients, healthcare visits, ADRs, PADRs, patients with PADRs,
and healthcare visits with PADRs were extracted by two
researchers. The first (KH) extracted the data, and the second
(KMH) confirmed the accuracy and completeness of the
extraction. Any disagreements were noted and resolved by
consensus. The extracted data were based on information reported
in or calculated from the included articles. Authors were not
contacted for complementary information.
The number of PADRs in each study represented the sum of
definitely, probably or possibly preventable cases, as reported in
original studies. The percentage of patients with PADRs was
calculated by dividing the reported number of healthcare visits
(such as primary or emergency care visits or hospitalisations) with
PADRs by the total number of healthcare visits. The percentages
could be calculated only if the number of healthcare visits were
interpretable in the original studies. The preventability of ADRs
was calculated by dividing the number of PADRs by the total
number of ADRs. If the number of PADRs, ADRs, healthcare
visits or healthcare visits with PADRs was not directly reported,
the two reviewers assessed whether they were interpretable based
on other presented data.
Risk of bias
The two reviewers (KH, KMH) assessed independently the
quality and the risk of bias in the original studies in conjunction
with data extraction. To minimise inconsistent estimates, we
required a standardised definition for ADRs [16,17], a case by case
assessment of preventability, and more inclusive data sources than
spontaneous reports or International Classification Disease (ICD-9
or 10) codes exclusively. No scoring system for quality assessment of
Figure 1. Search strategy used in the search of eight
bibliographic databases.
doi:10.1371/journal.pone.0033236.g001
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scoring of observational epidemiological studies exists [21].
Statistical analysis
Meta-analysis was performed using DerSimonian and Laird
random effect model with the estimate of heterogeneity being taken
from the inverse variance fixed effect model [22]. The summary
measures for the percentage of patients with PADRs and for the
preventability of ADRs were calculated separately for ADRs
occurring in outpatients and for ADRs present among inpatients
during hospitalisation. Studies on the elderly were analysed
separately. For the percentage of patients with PADRs, we first
converted the individual percentage estimates to logit to meet the
normal distribution assumption, conducted the analysis on the logit
and converted the final results into non-logit for interpretation.
Preventability estimates werecalculated without converting them into
logit in the analysis, because overall estimates using direct and logit
methods differed less than one percentage when they were compared.
Confidence intervals (95%) for each summary measure were
calculated. STATA software version 10 was used for data analysis.
To investigate the robustness of the overall estimates, we
conducted sensitivity analyses. Each analysis was conducted
separately for studies with less than six months’ study period and
with six months’ or longer study period, because studies with
longer study periods may more likely include revisits of the same
patients. Moreover, outlier studies whose estimates differed 20%
or more from the overall estimate were omitted from each analysis.
We also assessed the possibility of publication bias by evaluating
funnel plots. No asymmetry was evident. Heterogeneity was
explored using Cochrane’s Q test of heterogeneity and I
2 statistics.
Figure 2. Flow diagram of the selection of eligible studies on preventable adverse drug reactions (ADR).
doi:10.1371/journal.pone.0033236.g002
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According to Swedish regulations on medical research on
humans, approval by an ethical review board is not required in
review studies and meta-analyses that use aggregated patient data
from previous studies. As no individual patient data was used or
stored for the current study, informed consents from the
participants of the original studies were not required.
Results
A total of 5770 citations were found from electronic database
searches and additional 59 records were identified from reference
lists (Figure 2). After removal of duplicate records, the inclusion
and exclusion criteria were applied on 4220 unique citations. After
title and abstract review, the inclusion and exclusion criteria were
applied on 399 articles’ full texts. Most full-text articles were
excluded due to not assessing or reporting the percentage of
patients with PADRs or the preventability of ADRs (n=290).
Excluded articles commonly focused on potential drug-related
problems or other types of adverse events without a category for
ADRs or their preventability. Many also lacked a denominator for
calculating the percentage of patients or preventability. After
applying all inclusion criteria, we finally included 22 articles in the
review. Of these, 14 studies reported PADRs among outpatients
exclusively, six among inpatients, and two separately for
outpatients and inpatients (Tables 1,2,3).
Table 1. Characteristics of included studies on preventable adverse drug reactions among outpatients being hospitalised
w.
Study (Country) Study period Study design
Population
characteristics
Characteristics of
patients with ADR
Definition
for ADR
{
Criteria for
preventability
Pearson 1994 [23]
(United States)
{
6 months,
1992–1993
Prospective,
observational
No age limitation Mean age unknown,
50% male
Similar to
WHO [16]
Schumock [40]
Courtman 1995
[24] (Canada)
20 weeks,
1992–1993
Prospective,
observational
Age.65 years, median
78 years (range 65–108),
41% male
Unknown WHO [16] Modified Hallas [39]
Dartnell 1999
[25] (Australia)
30 days, 1994 Prospective,
observational
Median age 58 years
(range 15–91),
38% male
Unknown WHO [16] Own criteria
Chan 2001
[27] (Australia)
8 weeks, 1998 Cross-sectional,
observational
Mean age 82 years
(range 75–94),
45% male
Unknown WHO [16] Modified Hallas [39]
Olivier 2002
[28] (France)
Weeks, 1998 Prospective,
observational
Age.15 years Mean age 58 years,
54% male
WHO [16] Imbs [57] and own
criteria
#
Dormann 2003
[29] (Germany)
13 months,
1998–1999
Prospective,
observational
Mean age 54 years
(range 17–97),
85% male
Unknown WHO [16] Schumock [40]
Dormann 2004
[30] (Germany)
{
12 months+6
months
for related
readmission,
no year
Prospective,
observational
Mean age 57 years
(range 18–97), high
proportion of those
between 55–70 years
Unknown WHO [16] Schumock [40]
Pirmohamed 2004
[31] (United Kingdom)
6 months,
2000–2002
Prospective,
observational
Median age 66
years (range 46–79),
48% male
Median age 76
years (range 65–83),
41% male
Edwards and
Aronson [17]
Hallas [39]
Alexopoulou
2008 [33] (Greece)
6 months, 2005 Prospective
observational
Mean age 65 years
(range 15–100), 2/3
participants.65
years, 50% male
Mean age 71 years
(range 69–73),
47% male
WHO [16] Modified Hallas [39]
Fransceschi
2008 [34] (Italy)
14 months,
2004–2005
Prospective,
observational
Age $65 years Mean age 77 years
(range 60–93),
41% male
Edwards and
Aronson [17]
Hallas [39] integrated
with Gurwitz [58]
Hopf 2008 [35]
(United Kingdom)
2 weeks, 2006 Prospective,
observational
People without ADR:
mean age 62 years,
35% male
Mean age 67years
(range 19–91),
43% male
WHO [16] Hallas [39]
Ruiz 2008
[36] (Spain)*
21 months,
2001–2003,
for each
patient 60 days
Prospective,
observational
Unknown Aged.65 years
represent 65%,
58% male
WHO [16] Schumock [40]
Van Der Hooft
2008 [37]
(Netherlands)
12 months, 2003 Retrospective,
observational
Mean age 38
years, 48.5% male
Unknown Similar to
WHO [16]
Hallas [39]
ADR=adverse drug reaction; WHO=World Health Organization.
wADRs are present at admission and may or may not be the main reason for hospitalisation.
{Data from study used for analyses for both outpatients and inpatients.
*ADR reason for re-hospitalisation.
{Studies using WHO’s definition may have referenced another publication for the definition.
#Compared the two methods for assessing preventability of which the ‘‘own criteria’’ was chosen to be included in the meta-analysis.
doi:10.1371/journal.pone.0033236.t001
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Sixteen included studies reported PADRs among outpatients
being hospitalised or visiting emergency care (Tables 1,2) [23-38].
We did not identify any studies in primary care without a
hospitalisation or emergency visit. Nine studies were conducted in
Europe [28-31,33-37], two in Australia [25,27], four in North
America [23,24,26,38], and one India [32]. The studies were
conducted between 1992 and 2006. The study periods ranged
from two weeks [35] to 21 months [36]. Fourteen studies had a
prospective design [23-26,28-36,38], one retrospective [37], and
one cross-sectional [27]. All 16 studies used medical records as the
source of information, combined to reporting of ADRs or
interviewing patients or their family. Of these, 11 studies were
conducted in some wards [24-30,32-34,38], four included the
whole hospital [23,31,35,36], and one used a population database
of general practitioners as a source of recruitment [37]. Three
studies were conducted exclusively in the elderly ($65 years)
[24,27,34]. Except for two studies [24,32], all assessed the
preventability by the consensus of at least two professionals
[23,25-31,33-38]. For determining preventability, the criteria
introduced by Hallas [39] were used in nine of the 16 studies
[24,27,31-35,37,38], and Schumock’s criteria [40] in four
[23,29,30,36].
Eight included studies conducted between 1992 and 2009
investigated inpatients’ PADRs that were present during hospital-
isation (Table 3) [23,30,41-46]. All studies had a prospective
design. Four studies were conducted in Europe [30,43,44,46], one
in North America [23] and three in Iran [41,42,45]. The study
periods ranged from two weeks [43] to 18 months [44]. Except for
one study [46], all used medical records as the source of
information, combined to reporting of ADRs or interviewing
patients or their family. Five studies were conducted in some wards
Table 3. Characteristics of included studies on preventable adverse drug reactions among inpatients.
Study (Country) Study period Study design
Population
characteristics
Characteristics of
patients with ADRs
Definition
for ADR
{
Criteria for
preventability
Pearson 1994 [23]
(United States)
{
6 months,
1992–1993
Prospective,
observational
No age limitation Mean age unknown,
50% male
Similar to
WHO [16]
Schumock [40]
Gholami 1999
[41] (Iran)
4 months, 1996 Prospective,
randomised
for inclusion
No age limitation,
range 10–86 years
Unknown WHO [16] Schumock [40]
Dormann 2004
[30] (Germany)
{
12 months+6
months for related
readmission, no year
Prospective,
observational
Mean age 57 years
(range 18–97), high
proportion of those
between 55–70 years
Unknown WHO [16] Schumock [40]
Baniasadi 2008
[42] (Iran)
12 months,
2006–2007
Prospective,
interventional
No age limitation Unknown WHO [16] Schumock [40]
Davies 2006 [43]
(United Kingdom)
2 weeks, 2005 Prospective,
observational
Median age 61 years
(range 45–78),
51% male
Median age 70 years
(range 52–79),
38% male
Edwards and
Aronson [17]
Hallas [39]
Davies 2009 [44]
(United Kingdom)
6 months, 2005 Prospective,
observational
Median age of people
without ADR 61 years
Median age 72 years,
41% male
Edwards and
Aronson [17]
Hallas [39]
Pourseyed
2009 [45] (Iran)
15 weeks, 2004 Prospective,
observational
Mean age 60 years
(range 13–91), 78%
between 40–79
years, 51% male
Mean age 54 years,
43% male
WHO [16] Schumock [40]
Farcas 2010
[46] (Romania)
12 months, 2009 Prospective,
observational
Mean age 59 years
(range 25–92),
47% male
Mean age 65
years, 31% male
WHO [16] Imbs [57]
ADR=adverse drug reaction; WHO=World Health Organization.
{Data from study used for analyses on preventable adverse drug reactions for both outpatients and inpatients.
{Studies using WHO’s definition may have referenced another publication for the definition.
doi:10.1371/journal.pone.0033236.t003
Table 2. Characteristics of included studies on preventable adverse drug reactions among outpatients visiting emergency care.
Study (Country)
Study
period Study design
Population
characteristics
Characteristics of
patients with ADR
Definition for
ADR
{
Criteria for
preventability
Patel 2007
[32] (India)
6 weeks,
2005
Prospective,
observational
Age.18 years Mean age 40 years. WHO [16] Modified Hallas [39]
Zed 2008
[38] (Canada)
12 weeks,
2006
Prospective,
observational
Mean age 50 years, 48%
male
Unknown Similar to WHO [16] Hallas [39]
Tafreshi 1999
[26] (United States)
35 days,
1996
Prospective,
observational
Mean age 53 years
(range 0, 1–95), 43% male
Unknown Similar to WHO [16] Own criteria
ADR=adverse drug reaction; WHO=World Health Organization.
{Studies using WHO’s definition may have referenced another publication for the definition.
doi:10.1371/journal.pone.0033236.t002
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All studies included adults of all ages. In six studies [23,30,43-46],
preventability was assessed by the consensus of at least two
professionals, and the number of assessors was unclear in two
[41,42]. All studies [23,30,41-45], except for one [46], used either
Hallas [39] or Schumock [40] criteria for determining prevent-
ability.
Preventable adverse drug reactions among outpatients
The 16 studies on outpatients involved 48797 emergency
visits or hospital admissions. PADRs occurred in 2% (95%
confidence interval (CI): 1.2–3.2%) of outpatients (Figure 3),
and 52% (95% CI: 42–62%) of ADRs present at the time of
hospitalisation or an emergency vis i tw e r ep r e v e n t a b l e( F i g u r e4 ) .
The preventability was higher in the three studies including only
the elderly, for which 71% (95% CI: 51–91%) of ADRs were
preventable.
Preventable adverse drug reactions among inpatients
In total 24128 inpatients were included in the eight studies on
ADRs present during hospital stay. In inpatients, 1.6% (95%
CI: 0.1–51%) experienced a PADR during hospital stay (Figure 5).
Among inpatients, we found that 45% (95% CI: 33–58%) of
ADRs were assessed as preventable (Figure 6).
Figure 3. Percentage of patients with preventable adverse drug reactions among outpatients being hospitalised or visiting
emergency care. *not provided directly in the study, interpreted from other presented data.
doi:10.1371/journal.pone.0033236.g003
Figure 4. Preventability of adverse drug reactions among outpatients being hospitalised or visiting emergency care. *not provided
directly in the study, interpreted from other presented data.
doi:10.1371/journal.pone.0033236.g004
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The preventability of ADRs among outpatients and inpatients
and the percentage of outpatients with PADRs were higher in
studies with shorter study periods. When outliers were removed
from the main analysis, the preventability of ADRs among
outpatients was 45% (95% CI: 40–59%), lower than in the main
analysis. The preventability of ADRs among inpatients was 54%
(95% CI: 51–56%), higher than in the main analysis, when outliers
were removed. However, all sensitivity analyses’ estimates, both
according to study period and after removal of outliers, were
within the confidence intervals of the overall estimates of the main
analyses.
Discussion
We found that 2% of adult outpatients being hospitalised or
visiting emergency care experience PADRs. Approximately half of
all ADRs among outpatients were preventable. As no studies in
primary care were identified, the percentage of patients with
PADRs and the preventability of ADRs remain unknown among
outpatients without an admission or emergency visit. Among
inpatients, close to half of ADRs present during hospitalisation
were preventable, but the percentage of inpatients with PADRs
could not be estimated precisely.
Strengths and limitations of the review
Our study is the first to estimate in a meta-analysis the
percentage of patients with PADRs and the preventability of
ADRs, among both outpatients and inpatients. Our search
strategy was comprehensive, but laborious with a large number
of citations. We included published studies in English, as research
is to be shared internationally, but this may have lead to
overlooking some relevant studies. Authors were not contacted
for unpublished data which may have lead to excluding studies
that would have fulfilled the inclusion criteria if more data had
been available. Further, although an excluded full-text article
could include several exclusion criteria, only one exclusion
criterion per article was recorded in the order of notifying the
criterion. As it was not interpretable in most original studies
whether ADRs were incident or prevalent, we used the percentage
of patients with PADRs as an outcome measure. To prevent
heterogeneous estimates and avoid bias, we required a standard-
ised definition for ADRs, inclusive data sources and an original
preventability assessment. Yet, the included studies were hetero-
geneous, perhaps due to varying study designs, settings and criteria
for preventability. However, our overall estimates did not differ
substantially when two sensitivity analyses were performed.
We found ADRs among adult outpatients more preventable
than in earlier reviews, in which the median and pooled
preventability of ADRs among patients being hospitalised has
been 31% and 29%, respectively [4,10]. The difference may arise
from inconsistent definitions for ADRs. For providing consistent
estimates, we required WHO’s [16] or a similar [17] definition for
ADRs. Studies included in previous reviews on outpatients
accepted various definitions for ADRs [4,10], some of which
found ADRs less preventable [47-50]. The criteria for prevent-
ability may also have influenced differing preventability estimates.
While it was not an inclusion criterion, most studies in our meta-
analysis used the criteria introduced by Hallas et al [39] or
Schumock et al [40] to establish preventability. Some studies in
Figure 5. Percentage of inpatients with preventable adverse drug reactions, during hospitalisation. *not provided directly in the study,
interpreted from other presented data.
doi:10.1371/journal.pone.0033236.g005
Figure 6. Preventability of adverse drug reactions among inpatients, during hospitalisation. *not provided directly in the study,
interpreted from other presented data.
doi:10.1371/journal.pone.0033236.g006
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sively inappropriate drug selection or dose [47] and unnecessary
therapy [51] preventable. Thus, preventability due to other
reasons, such as lack of monitoring or prescribing a prophylactic
medication for an expected ADR, may have been overlooked in
previous studies resulting in lower preventability estimates. In
addition, 12 out of 16 articles on outpatients in our meta-analysis
were published in the 21
st century while all articles in the previous
reviews on PADRs were published in the 20
th century. Even
though it may not be concluded from our results that the
preventability of ADRs among outpatients would have increased
over time, the increasing interest in and discussion on patient
safety since the late 1990s’ [52] may have fostered acknowledging
preventability in newer studies.
The lack of other review studies on the percentage of
outpatients with PADRs or the preventability of ADRs among
inpatients hinders comparison to previous evidence. In one review
on all drug-related adverse events, at median 4.3% of all
admissions among outpatients were considered drug-related and
preventable [11]. Their higher estimate compared to ours on
PADRs exclusively (2%) was expected, as they included events
beyond ADRs, such as therapeutic failures, drug intoxications and
misuse. Among inpatients, previous reviews have found that the
median preventability of all drug-related adverse events is 35%
and 46% [6,12], ranging between 19% and 90% in individual
studies. These are comparable to our estimate that 45% of ADRs
are preventable among inpatients experiencing ADRs during
hospital stay. Compared to previous reviews, our meta-analysis
provides more consistent estimates on the preventability of ADRs
and the proportion of patients with PADRs as our outcome
measure is more standardised.
Study implications
This meta-analysis demonstrates that PADRs are a significant
cause of morbidity among outpatients and that roughly half of all
ADRs among adult outpatients and inpatients may be prevented.
In the included articles resulting in these preventability estimates, a
common criteria for preventability was ‘‘the drug event was due to a
drug treatment procedure inconsistent with present-day knowledge of good
medical practice or was clearly unrealistic, taking the known circumstances into
account’’ [39]. Others considered ADRs preventable when they
occurred due to contraindications, inappropriate dose or moni-
toring, interactions, ignoring toxic serum drug concentrations or
previous allergic reactions, or noncompliance [40]. ADRs
occurring for these reasons need to be diminished to reduce the
burden of ADRs, related costs [31,44], and unnecessary patient
harm. Thus, effective intervention strategies and safety measures
for preventing ADRs need to be incorporated into healthcare in
system-level. As support for prevention strategies, such as
medication reviews, to reduce medication-related harm is limited
[53], further evidence on interventions to prevent ADRs and their
implementation in healthcare is required. However, errors related
to use of medications will to some extent always occur mainly due
to the human imperfection in mental functioning and due to the
complex nature of medical practice [54].
Our meta-analysis also highlights the lack of evidence on
PADRs. Despite our thorough search strategy, we did not identify
studies on PADRs occurring in primary care. Thus, our findings
are likely to represent only the most serious PADRs among
outpatients. Further, only two studies allowed estimating the
percentage of inpatients with PADR, and the generated overall
estimate was imprecise. Therefore, future research should
investigate PADRs in the general population, especially among
people without emergency visits or hospitalisation and among
inpatients during hospital stay. As identified in previously [55,56],
better consensus on defining and assessing preventability should
also be reached to decrease heterogeneity between studies and
enable more precise estimates in future meta-analyses.
This meta-analysis corroborates that PADRs are a significant
burden to healthcare among adult outpatients. Among both
outpatients and inpatients, approximately half of all ADRs are
preventable. Although preventability estimates vary across studies,
our results demonstrate that further evidence on prevention
strategies is required. The percentage of patients with PADRs
among inpatients and in primary care is largely unknown and
should be investigated in future research.
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